AptarGroup, Inc. (ATR) Stock: Price, Forecast & Analyst Target
AptarGroup, Inc. (ATR) — MoonshotScore 77/100 (Strong band), calculated Nov 18, 2026. Price $140.34 (-0.94%), as of the Nov 19, 2026 trading session; market cap $8.90B. Expected results Feb 4, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 41.92× (cash as of Sep 30, 2026) · expected results Feb 4, 2027
AptarGroup, Inc. · ATR · NYSE · Healthcare · Medical - Instruments & Supplies
Research dated 2026-09-13: AptarGroup supplies the pumps, valves, closures, seals and elastomer components that control how medicines, beauty products, household goods, food and beverages are dispensed. Its prospects depend on whether growth in pharmaceutical components and restored Beauty plus Home pricing can support earnings while capital investment and debt continue to absorb financial capacity.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · AptarGroup (ATR)
StrongWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality and durable growth, but a full valuation; the market is already moving on it. Business Quality: Solid; Financial Safety: Sound; Valuation: Full; Growth Durability: Growing; Momentum: Surging.
- EPS beat 0 of the last 4 reports
- Altman Z 4.13 · Piotroski F 7
- ROE 10.1% · ROA 5.2% · current ratio 1.50 · earnings yield 3.0% · free-cash-flow yield 3.3%
Helping: business quality, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 78 | Strong | |
| 78 | Strong | |
| 78 | Strong | |
| 78 | Strong | |
| 77 | Strong | |
| 77 | Strong |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $140.34 | |
| Change on the day | -0.94% | |
| 52-week range | $110.95–$148.63 | |
| Market capitalisation | $8.90B | — |
| Price / earnings (trailing) | 33.73 | |
| Shares traded on the day | 442.8K | |
| Beta (volatility vs the S&P 500) | 0.32 | |
| Dividends per share (last 12 months) | $1.94 | |
| Dividend yield (last 12 months) | 1.38% |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings call · management outlook
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
We anticipate fourth quarter adjusted earnings per share to be in the range of $1.39 to $1.47.
Vanessa Kanu · Statement from
For the full year 2026, we continue to expect capital investments to be in the range of $260 million to $280 million and depreciation and amortization expense to be between $310 million and $320 million.
Vanessa Kanu · Statement from
How to read these dates
Events are in date order; the spacing is not a duration scale. A statement's date is the earnings call where it was made, not a deadline. Management expectations and estimated dates can change.
Other perspectives
Council score for AptarGroup (ATR): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 19, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 19, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
The Munger lens reads the current price as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is AptarGroup (ATR), and what does it report?
Short answer · as of
Aptar does not sell medicines, cosmetics or beverages.
Research dated 2026-09-13.
It sells the delivery and sealing hardware used inside those products, including nasal pumps, inhaler valves, injectable packaging, beauty pumps, aerosol valves, flow-control parts and closures. Demand therefore follows customer production volumes, product mix and the value of the component supplied.
Reporting follows Pharma, Beauty plus Home, and Food plus Beverage. Pharma includes drug-delivery and injectable components as well as active material science, while the consumer-facing businesses supply dispensing and closure systems for beauty, personal care, household, food and beverage customers. Among the disclosed segment totals, Pharma contributes more revenue than Beauty.
What do the latest results show for AptarGroup (ATR)?
Research dated 2026-09-13.
The latest period extended the upward sales progression: revenue advanced from the prior period and from the comparable period. Gross profit, operating profit and net income also improved sequentially, yet each remained below its comparable-period level. Reported revenue and earnings cleared consensus in the latest release.
Management attributed part of the Beauty margin pressure to delayed pricing pass-through and said that delay should be resolved in the following period. That explanation creates a direct test: Beauty profitability should improve if customer pricing catches up, even without relying on a major change in sales volume.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $1.02B Sep 30, 2026
- Latest quarter · R&D
- $160.16M Sep 30, 2026
- Latest quarter · SG&A
- $0.00 Sep 30, 2026
- Latest quarter · FMP standardized operating result
- $135.01M Sep 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | $1.02B | $160.16M | $0.00 | $135.01M |
| Jun 30, 2026 | $1.03B | $157.74M | $167.56M | $128.14M |
| Mar 31, 2026 | $982.87M | $167.60M | $167.56M | $108.63M |
| Dec 31, 2025 | $962.74M | Not available | $150.95M | $110.69M |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $1.02B Oct 29, 2026
- Latest report · revenue estimate
- $980.76M Oct 29, 2026
- Latest report · revenue vs estimate
- Above estimate Oct 29, 2026
- Latest report · EPS vs estimate
- Above estimate Oct 29, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Oct 29, 2026 | $1.02B | $980.76M | $1.5200 | $1.4700 |
| Jul 30, 2026 | $1.03B | $1.01B | $1.4200 | $1.3500 |
| Apr 30, 2026 | $982.87M | $955.95M | $1.1900 | $1.1500 |
| Feb 5, 2026 | $962.74M | $878.58M | $1.2500 | $1.2400 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Jun 2025 | $966M | $112M | $1.67 (diluted) |
| Q3 FY2025 | $961M | $128M | $1.92 (diluted) |
| Q4 FY2025 | $963M | $74M | $1.13 (diluted) |
| Q1 FY2026 | $983M | $73M | $1.12 (diluted) |
What are the financial strengths and risks for AptarGroup (ATR)?
Short answer
Cash and short-term investments were $212.30M at the Sep 30, 2026 balance-sheet date. Operating cash flow was $167.60M for the quarter ended Sep 30, 2026, meaning operations generated cash. These figures do not establish a cash runway.
Research dated 2026-09-13.
Operating cash flow remained positive throughout the reported series and exceeded capital spending in every period shown. The residual cash generation is meaningful, but recent operating cash flow has softened from earlier highs while management continues to plan substantial investment.
Cash and short-term investments declined across the reported window, and total debt remains far above liquid resources even after including long-term investments. Near-term liquidity ratios remain above parity, but this is not a net-cash balance sheet. Regular dividend payments add a recurring use of cash.
The financial tension is specific to Aptar's model: capital spending must support manufacturing capacity and specialized components, while delayed price recovery can compress Beauty margins before customer pricing catches up. Persistent cash erosion alongside heavy investment or another pricing lag would weaken the case.
Data-derived red flags
- Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
- Rich valuation — a P/E of 33.73 runs well above the Healthcare sector’s ~21.70x, leaving little room for a miss.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- $167.60M Sep 30, 2026
- Previous quarter · operating cash flow
- $103.49M Jun 30, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Sep 30, 2026 | $167.60M | −$69.01M |
| Jun 30, 2026 | $103.49M | −$57.56M |
| Mar 31, 2026 | $118.69M | −$65.40M |
| Dec 31, 2025 | $183.69M | −$86.82M |
How to read these figures
Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.
What should you watch next at AptarGroup (ATR)?
Short answer · as of
The next earnings report is expected on Feb 4, 2027.
Research dated 2026-09-13.
Beauty plus Home margin is the immediate operating checkpoint. Improvement would support management's claim that delayed pricing was temporary; continued pressure would point to weaker pass-through or a broader profitability problem. Gross profit and operating profit should therefore be read alongside revenue rather than treated as automatic consequences of sales growth.
Cash conversion is the other checkpoint. Compare operating cash flow with capital spending, then watch whether cash and short-term investments stabilize against the debt load. The scheduled earnings release and management's earnings outlook provide the next formal tests, while longer-range consensus assumes continued revenue and earnings expansion that still needs confirmation in reported results.
What management is planning
How does AptarGroup compare with its peers?
Short answer
AptarGroup's score ranks 5th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
Aptar is broader than its healthcare classification suggests. Pharma is the larger disclosed segment, but the company also sells beauty pumps, household dispensers, food closures and beverage flow-control components. This creates exposure to regulated drug-delivery demand and consumer packaging demand within the same manufacturer.
Compared with a drugmaker, Aptar's revenue comes from components incorporated into customer products rather than from therapeutic ownership. Compared with a beauty-focused dispenser supplier, its nasal pumps, inhaler valves and injectable elastomer packaging add a pharmaceutical component base. The trade-off is that specialized Pharma demand and consumer-facing pricing cycles can pull profitability in different directions.
| Company | Price | Market value | Score |
|---|---|---|---|
| $93.04 Nov 19, 2026 | $10.6B | 95 5-pillar Nov 18, 2026 | |
| $70.53 Nov 18, 2026 | $9.34B | 94 5-pillar Nov 18, 2026 | |
| $120.37 Nov 19, 2026 | $5.48B | 83 5-pillar Nov 18, 2026 | |
| $84.41 Nov 19, 2026 | $5.06B | 81 5-pillar Nov 18, 2026 | |
| AptarGroup (ATR) — this page | $140.34 | $8.90B | 77 |
| $84.80 Nov 19, 2026 | $9.37B | 73 5-pillar Nov 18, 2026 | |
| $175.76 Nov 19, 2026 | $4.40B | 73 5-pillar Nov 18, 2026 | |
| $15.93 Nov 19, 2026 | $4.35B | 73 5-pillar Nov 18, 2026 | |
| $15.12 Nov 19, 2026 | $10.3B | 71 5-pillar Nov 18, 2026 | |
| $170.29 Nov 19, 2026 | $10.9B | 71 5-pillar Nov 18, 2026 | |
| $203.34 Nov 19, 2026 | $10.6B | 68 5-pillar Nov 18, 2026 | |
| $163.40 Nov 19, 2026 | $6.48B | 61 5-pillar Nov 18, 2026 | |
| $25.39 Nov 19, 2026 | $13.1B | 57 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $135.00 – $160.00
- Consensus target
- $150.00
- Median target
- $152.50
Consensus record · Captured .
Measured against a quoted price of $140.34 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 500 records, those within the last 180 days, newest dated Nov 5, 2026
- Transactions
- 29
- Identified insiders
- 16
- Purchases
- 0
- Sales
- 14
- Other transactions
- 15
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 96.5% Period end Sep 30, 2026
- Previous quarter · ownership
- 97.0% Prior to period end Sep 30, 2026
- Reporting holders
- 544 Period end Sep 30, 2026
- Previous quarter · holders
- 565 Prior to period end Sep 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Blackrock, INC. | 6,193,454 |
| State Farm Mutual Automobile Insurance Co | 4,744,564 |
| Vanguard Portfolio Management LLC | 3,625,137 |
| Morgan Stanley | 3,400,650 |
| Vanguard Capital Management LLC | 2,885,239 |
Tracked investors
Which of the 16 named investors we follow held ATR in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported ATR in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about AptarGroup (ATR)?
What Investors Ask About AptarGroup (ATR) — Healthcare
Research dated 2026-09-13; the full attribution is under Sources. The last 3 questions are answered from this page's own dated data, not from the research.
What does Aptar Pharma supply to drugmakers?
Aptar Pharma supplies nasal pumps, metered-dose inhaler valves, elastomer packaging for injectables and active material science solutions. Its economics come from the delivery and protection components used with therapies, not from ownership of the drugs themselves.
Why is Beauty plus Home pricing important for Aptar?
A lag in passing costs through to Beauty customers reduced segment margin, according to management. Margin recovery would indicate that customer pricing has caught up; continued pressure would challenge that explanation.
What is Aptar developing with PureCycle?
Aptar is working with PureCycle to integrate ultra-pure recycled polypropylene into advanced dispensing applications. The effort links recycled material inputs with Aptar's core dispensing designs.
Does Aptar generate cash after capital spending?
Operating cash flow exceeded capital spending throughout the reported series, leaving positive residual cash generation. Even so, cash and short-term investments declined across the window, while debt remained larger than liquid resources.
What is the ATR stock price today?
The last price recorded for AptarGroup, Inc. (ATR), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the ATR price target?
The analyst consensus price target for AptarGroup, Inc. (ATR), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Does ATR pay a dividend?
Yes. The dividend yield of AptarGroup, Inc. (ATR) over the last 12 months, with its date, is listed under Price & valuation on this page. Payout ratio and cash-flow coverage decide whether it can last, and past dividends do not guarantee future payments.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 82 figures on this page — 2 from SEC filings and earnings calls, 71 from Financial Modeling Prep (FMP), 3 with no recorded source, 5 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com